Relationship between Serum Proprotein Convertase Subtilisin/Kexin Type 9 Concentration and Prevalence of Coronary Artery Calcium in a Community-Based Sample of Japanese Men
Aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising new target for reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular events in high-risk patients. However, the influence of circulating PCSK9 concentration on atherosclerotic plaque formation in the general...
Saved in:
| Published in | Journal of Atherosclerosis and Thrombosis Vol. 30; no. 7; pp. 767 - 777 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Japan
Japan Atherosclerosis Society
01.07.2023
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1340-3478 1880-3873 1880-3873 |
| DOI | 10.5551/jat.63549 |
Cover
| Abstract | Aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising new target for reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular events in high-risk patients. However, the influence of circulating PCSK9 concentration on atherosclerotic plaque formation in the general population remains unknown. We assessed the relationship between serum PCSK9 concentration and coronary artery calcium (CAC) prevalence in the general population.Methods: Community-dwelling Japanese men (n=622) aged 46–82 years without a history of cardiovascular disease and lipid-lowering medications were included. Serum PCSK9 concentration and CAC score were measured using the Agatston method, and the multivariable analysis was used to assess their association. CAC was defined as an Agatston score of ＞10. We conducted further analysis stratified by age (＜60, 60–69, and ≥ 70 years).Results: The average age, LDL-C, and median serum PCSK9 concentration were 68 years, 122 mg/dL, and 240 ng/mL, respectively. After multivariable adjustment for traditional cardiovascular risk factors, no significant association was observed between serum PCSK9 concentration and CAC prevalence (adjusted relative risk [aRR] 1.05, 95% confidence interval [CI] 0.97–1.13). With age stratification, serum PCSK9 concentration was significantly associated with CAC prevalence in men aged ＜60 years (aRR 1.38, 95% CI 1.01–1.88) but not in men aged 60–69 years (aRR 0.96, 95% CI 0.85–1.10) or ≥ 70 years (aRR 1.08, 95% CI 0.99–1.19).Conclusions: A higher serum PCSK9 concentration was associated with a higher CAC prevalence in men aged ＜60 years, which was independent of traditional cardiovascular risk factors. |
|---|---|
| AbstractList | Aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising new target for reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular events in high-risk patients. However, the influence of circulating PCSK9 concentration on atherosclerotic plaque formation in the general population remains unknown. We assessed the relationship between serum PCSK9 concentration and coronary artery calcium (CAC) prevalence in the general population. Methods: Community-dwelling Japanese men (n=622) aged 46-82 years without a history of cardiovascular disease and lipid-lowering medications were included. Serum PCSK9 concentration and CAC score were measured using the Agatston method, and the multivariable analysis was used to assess their association. CAC was defined as an Agatston score of >10. We conducted further analysis stratified by age (<60, 60-69, and >=70 years). Results: The average age, LDL-C, and median serum PCSK9 concentration were 68 years, 122 mg/dL, and 240 ng/mL, respectively. After multivariable adjustment for traditional cardiovascular risk factors, no significant association was observed between serum PCSK9 concentration and CAC prevalence (adjusted relative risk [aRR] 1.05, 95% confidence interval [CI] 0.97-1.13). With age stratification, serum PCSK9 concentration was significantly associated with CAC prevalence in men aged <60 years (aRR 1.38, 95% CI 1.01-1.88) but not in men aged 60-69 years (aRR 0.96, 95% CI 0.85-1.10) or >=70 years (aRR 1.08, 95% CI 0.99-1.19). Conclusions: A higher serum PCSK9 concentration was associated with a higher CAC prevalence in men aged <60 years, which was independent of traditional cardiovascular risk factors. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising new target for reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular events in high-risk patients. However, the influence of circulating PCSK9 concentration on atherosclerotic plaque formation in the general population remains unknown. We assessed the relationship between serum PCSK9 concentration and coronary artery calcium (CAC) prevalence in the general population.AIMSProprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising new target for reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular events in high-risk patients. However, the influence of circulating PCSK9 concentration on atherosclerotic plaque formation in the general population remains unknown. We assessed the relationship between serum PCSK9 concentration and coronary artery calcium (CAC) prevalence in the general population.Community-dwelling Japanese men (n=622) aged 46-82 years without a history of cardiovascular disease and lipid-lowering medications were included. Serum PCSK9 concentration and CAC score were measured using the Agatston method, and the multivariable analysis was used to assess their association. CAC was defined as an Agatston score of ＞10. We conducted further analysis stratified by age (＜60, 60-69, and ≥ 70 years).METHODSCommunity-dwelling Japanese men (n=622) aged 46-82 years without a history of cardiovascular disease and lipid-lowering medications were included. Serum PCSK9 concentration and CAC score were measured using the Agatston method, and the multivariable analysis was used to assess their association. CAC was defined as an Agatston score of ＞10. We conducted further analysis stratified by age (＜60, 60-69, and ≥ 70 years).The average age, LDL-C, and median serum PCSK9 concentration were 68 years, 122 mg/dL, and 240 ng/mL, respectively. After multivariable adjustment for traditional cardiovascular risk factors, no significant association was observed between serum PCSK9 concentration and CAC prevalence (adjusted relative risk [aRR] 1.05, 95% confidence interval [CI] 0.97-1.13). With age stratification, serum PCSK9 concentration was significantly associated with CAC prevalence in men aged ＜60 years (aRR 1.38, 95% CI 1.01-1.88) but not in men aged 60-69 years (aRR 0.96, 95% CI 0.85-1.10) or ≥ 70 years (aRR 1.08, 95% CI 0.99-1.19).RESULTSThe average age, LDL-C, and median serum PCSK9 concentration were 68 years, 122 mg/dL, and 240 ng/mL, respectively. After multivariable adjustment for traditional cardiovascular risk factors, no significant association was observed between serum PCSK9 concentration and CAC prevalence (adjusted relative risk [aRR] 1.05, 95% confidence interval [CI] 0.97-1.13). With age stratification, serum PCSK9 concentration was significantly associated with CAC prevalence in men aged ＜60 years (aRR 1.38, 95% CI 1.01-1.88) but not in men aged 60-69 years (aRR 0.96, 95% CI 0.85-1.10) or ≥ 70 years (aRR 1.08, 95% CI 0.99-1.19).A higher serum PCSK9 concentration was associated with a higher CAC prevalence in men aged ＜60 years, which was independent of traditional cardiovascular risk factors.CONCLUSIONSA higher serum PCSK9 concentration was associated with a higher CAC prevalence in men aged ＜60 years, which was independent of traditional cardiovascular risk factors. Aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising new target for reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular events in high-risk patients. However, the influence of circulating PCSK9 concentration on atherosclerotic plaque formation in the general population remains unknown. We assessed the relationship between serum PCSK9 concentration and coronary artery calcium (CAC) prevalence in the general population. Methods: Community-dwelling Japanese men ( n =622) aged 46–82 years without a history of cardiovascular disease and lipid-lowering medications were included. Serum PCSK9 concentration and CAC score were measured using the Agatston method, and the multivariable analysis was used to assess their association. CAC was defined as an Agatston score of ＞10. We conducted further analysis stratified by age (＜60, 60–69, and ≥ 70 years). Results: The average age, LDL-C, and median serum PCSK9 concentration were 68 years, 122 mg/dL, and 240 ng/mL, respectively. After multivariable adjustment for traditional cardiovascular risk factors, no significant association was observed between serum PCSK9 concentration and CAC prevalence (adjusted relative risk [aRR] 1.05, 95% confidence interval [CI] 0.97–1.13). With age stratification, serum PCSK9 concentration was significantly associated with CAC prevalence in men aged ＜60 years (aRR 1.38, 95% CI 1.01–1.88) but not in men aged 60–69 years (aRR 0.96, 95% CI 0.85–1.10) or ≥ 70 years (aRR 1.08, 95% CI 0.99–1.19). Conclusions: A higher serum PCSK9 concentration was associated with a higher CAC prevalence in men aged ＜60 years, which was independent of traditional cardiovascular risk factors. Aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising new target for reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular events in high-risk patients. However, the influence of circulating PCSK9 concentration on atherosclerotic plaque formation in the general population remains unknown. We assessed the relationship between serum PCSK9 concentration and coronary artery calcium (CAC) prevalence in the general population.Methods: Community-dwelling Japanese men (n=622) aged 46–82 years without a history of cardiovascular disease and lipid-lowering medications were included. Serum PCSK9 concentration and CAC score were measured using the Agatston method, and the multivariable analysis was used to assess their association. CAC was defined as an Agatston score of ＞10. We conducted further analysis stratified by age (＜60, 60–69, and ≥ 70 years).Results: The average age, LDL-C, and median serum PCSK9 concentration were 68 years, 122 mg/dL, and 240 ng/mL, respectively. After multivariable adjustment for traditional cardiovascular risk factors, no significant association was observed between serum PCSK9 concentration and CAC prevalence (adjusted relative risk [aRR] 1.05, 95% confidence interval [CI] 0.97–1.13). With age stratification, serum PCSK9 concentration was significantly associated with CAC prevalence in men aged ＜60 years (aRR 1.38, 95% CI 1.01–1.88) but not in men aged 60–69 years (aRR 0.96, 95% CI 0.85–1.10) or ≥ 70 years (aRR 1.08, 95% CI 0.99–1.19).Conclusions: A higher serum PCSK9 concentration was associated with a higher CAC prevalence in men aged ＜60 years, which was independent of traditional cardiovascular risk factors. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising new target for reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular events in high-risk patients. However, the influence of circulating PCSK9 concentration on atherosclerotic plaque formation in the general population remains unknown. We assessed the relationship between serum PCSK9 concentration and coronary artery calcium (CAC) prevalence in the general population. Community-dwelling Japanese men (n=622) aged 46-82 years without a history of cardiovascular disease and lipid-lowering medications were included. Serum PCSK9 concentration and CAC score were measured using the Agatston method, and the multivariable analysis was used to assess their association. CAC was defined as an Agatston score of ＞10. We conducted further analysis stratified by age (＜60, 60-69, and ≥ 70 years). The average age, LDL-C, and median serum PCSK9 concentration were 68 years, 122 mg/dL, and 240 ng/mL, respectively. After multivariable adjustment for traditional cardiovascular risk factors, no significant association was observed between serum PCSK9 concentration and CAC prevalence (adjusted relative risk [aRR] 1.05, 95% confidence interval [CI] 0.97-1.13). With age stratification, serum PCSK9 concentration was significantly associated with CAC prevalence in men aged ＜60 years (aRR 1.38, 95% CI 1.01-1.88) but not in men aged 60-69 years (aRR 0.96, 95% CI 0.85-1.10) or ≥ 70 years (aRR 1.08, 95% CI 0.99-1.19). A higher serum PCSK9 concentration was associated with a higher CAC prevalence in men aged ＜60 years, which was independent of traditional cardiovascular risk factors. |
| ArticleNumber | 63549 |
| Author | Kadota, Aya Hisamatsu, Takashi Kondo, Keiko Miura, Katsuyuki Kunimura, Ayako Torii, Sayuki Nakagawa, Yoshihisa Ueshima, Hirotsugu Segawa, Hiroyoshi Okamura, Tomonori Fujiyoshi, Akira Yano, Yuichiro |
| Author_xml | – sequence: 1 fullname: Miura, Katsuyuki organization: NCD Epidemiology Research Center, Shiga University of Medical Science – sequence: 1 fullname: Fujiyoshi, Akira organization: Department of Hygiene, Wakayama Medical University – sequence: 1 fullname: Kondo, Keiko organization: NCD Epidemiology Research Center, Shiga University of Medical Science – sequence: 1 fullname: Ueshima, Hirotsugu organization: NCD Epidemiology Research Center, Shiga University of Medical Science – sequence: 1 fullname: Torii, Sayuki organization: Department of Public Health, Shiga University of Medical Science – sequence: 1 fullname: Okamura, Tomonori organization: Department of Preventive Medicine and Public Health, Keio University School of Medicine – sequence: 1 fullname: Hisamatsu, Takashi organization: Department of Public Health, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences – sequence: 1 fullname: Yano, Yuichiro organization: NCD Epidemiology Research Center, Shiga University of Medical Science – sequence: 1 fullname: Kunimura, Ayako organization: Department of Cardiology, Kobe Rosai Hospital – sequence: 1 fullname: Kadota, Aya organization: NCD Epidemiology Research Center, Shiga University of Medical Science – sequence: 1 fullname: Segawa, Hiroyoshi organization: NCD Epidemiology Research Center, Shiga University of Medical Science – sequence: 1 fullname: Nakagawa, Yoshihisa organization: Department of Cardiovascular Medicine, Shiga University of Medical Science |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36123046$$D View this record in MEDLINE/PubMed |
| BookMark | eNptUsuO0zAUjdAg5gELfgBlCYtO_YjtZIWGCobHIBAd1pbj3M64cuxgO2X6T3wkbjqUh1jEtnzOPcf3npwWR847KIqnGJ0zxvB8rdI5p6xqHhQnuK7RjNaCHuUzrfK5EvVxcRrjGiFKGSOPimPKMaGo4ifFjy9gVTLexVszlC2k7wCuXEIY-_Jz8EPwCYwrF95tICQVoVyObTLWROPmH-AuY9fbAcpmR9HgUpjUSuW6XA8bZSFfl36V8eCdCtvyIiTI20JZbbJLVlAZ7PvRmbSdvcoeXblU_WCnsvdqUA6y70dwj4uHK2UjPLnfz4qvb15fL97Orj5dvltcXM00r1ma0YZ1DKumboGvuoZApSlmXU0qzgWuCOZMtwS3SjVAecsUoYrpDgvGUcvz6M6Kl3vdYWx76PZtWTkE0-cGpFdG_o04cytv_EZiRAkRtMoKz-8Vgv82QkyyN1GDtbkXP0ZJBOaoFgTXmfrsT7ODy6-MMuHFnqCDjzHA6kDBSO7ylzl_OeWfufN_uNqkKZH8TmP_W3G5r8jeRivrnTUO5NqPweUZS7gTne-3ShJEqMy_EEJCTp_gu0WIihAqGP49tXVM6gYOr1QhGW1h8qRIit0yeR8QfauCBEd_ApOn40I |
| CitedBy_id | crossref_primary_10_1038_s41598_024_57708_5 crossref_primary_10_5551_jat_RV22009 |
| Cites_doi | 10.1253/circj.70.1249 10.1093/eurjpc/zwab154 10.1038/s41574-018-0110-5 10.1007/s40119-017-0092-8 10.1161/JAHA.112.001974 10.1056/NEJMoa1316222 10.1186/s12933-020-01142-0 10.1016/j.jacasi.2021.09.003 10.1074/jbc.M708098200 10.5551/jat.63159 10.2188/jea.JE20110138 10.1016/j.jacl.2017.01.005 10.1016/j.jacc.2006.10.079 10.1161/CIRCGENETICS.108.828467 10.1161/CIRCIMAGING.114.002262 10.1016/j.atherosclerosis.2020.09.013 10.1056/NEJMoa1801174 10.1016/0735-1097(90)90282-T 10.1016/j.atherosclerosis.2016.08.038 10.5551/jat.56390 10.1161/CIRCRESAHA.114.301621 10.1016/j.jacc.2008.03.047 10.1016/j.amjcard.2014.05.060 10.1016/j.atherosclerosis.2016.07.922 10.1074/jbc.M110.192104 10.1161/CIRCULATIONAHA.115.018531 10.1016/j.atherosclerosis.2015.12.027 10.1001/jama.2016.16951 10.1016/j.jacc.2014.03.018 10.1093/eurheartj/ehab484 10.1161/CIR.0000000000000624 10.1016/j.jacbts.2016.06.007 10.1074/jbc.M606495200 10.1093/aje/kwk053 10.1007/s12031-014-0238-2 10.1194/jlr.R800091-JLR200 10.5551/jat.RV17012 10.1093/clinchem/18.6.499 10.1210/jc.2009-0141 10.1016/j.ijcard.2016.04.103 10.1093/aje/kwh090 10.1194/jlr.M012526 10.1210/jc.2014-3066 10.5551/jat.17244 |
| ContentType | Journal Article |
| Copyright | This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License. 2023 Japan Atherosclerosis Society 2023 |
| Copyright_xml | – notice: This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License. – notice: 2023 Japan Atherosclerosis Society 2023 |
| CorporateAuthor | Department of Cardiovascular Medicine Department of Preventive Medicine and Public Health Department of Public Health NCD Epidemiology Research Center Dentistry and Pharmaceutical Sciences Shiga University of Medical Science Department of Cardiology Wakayama Medical University Okayama University Graduate School of Medicine Department of Hygiene Kobe Rosai Hospital Keio University School of Medicine |
| CorporateAuthor_xml | – name: Okayama University Graduate School of Medicine – name: Department of Cardiovascular Medicine – name: NCD Epidemiology Research Center – name: Dentistry and Pharmaceutical Sciences – name: Shiga University of Medical Science – name: Department of Public Health – name: Wakayama Medical University – name: Department of Preventive Medicine and Public Health – name: Department of Cardiology – name: Keio University School of Medicine – name: Kobe Rosai Hospital – name: Department of Hygiene |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.5551/jat.63549 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1880-3873 |
| EndPage | 777 |
| ExternalDocumentID | PMC10322734 36123046 10_5551_jat_63549 ex7domya_2023_003007_007_0767_07774223751 article_jat_30_7_30_63549_article_char_en |
| Genre | Journal Article |
| GroupedDBID | --- .55 29J 2WC 53G 5GY 5VS AAFWJ ACGFO ADBBV AENEX ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL DIK DU5 E3Z F5P GX1 HYE JMI JSF JSH KQ8 OK1 OVT P6G RJT RNS RPM RZJ TR2 X7M 3O- TKC AAYXX CITATION CGR CUY CVF ECM EIF GROUPED_DOAJ M~E NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c685t-395d51a98be6fd92e4c315d824667142165cb21baa9e36b5a23a5cd17560b6873 |
| ISSN | 1340-3478 1880-3873 |
| IngestDate | Thu Aug 21 18:37:07 EDT 2025 Thu Jul 10 19:22:25 EDT 2025 Thu Jan 02 22:43:51 EST 2025 Tue Jul 01 02:27:13 EDT 2025 Thu Apr 24 22:57:01 EDT 2025 Thu Jul 10 16:15:05 EDT 2025 Wed Sep 03 06:30:39 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 7 |
| Keywords | Coronary artery calcium Proprotein convertase subtilisin/kexin type 9 Atherosclerosis |
| Language | English |
| License | https://creativecommons.org/licenses/by-nc-sa/4.0 This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.http://creativecommons.org/licenses/by-nc-sa/4.0 |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c685t-395d51a98be6fd92e4c315d824667142165cb21baa9e36b5a23a5cd17560b6873 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 on behalf of the SESSA research group |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC10322734 |
| PMID | 36123046 |
| PQID | 2716087218 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10322734 proquest_miscellaneous_2716087218 pubmed_primary_36123046 crossref_primary_10_5551_jat_63549 crossref_citationtrail_10_5551_jat_63549 medicalonline_journals_ex7domya_2023_003007_007_0767_07774223751 jstage_primary_article_jat_30_7_30_63549_article_char_en |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2023-Jul-01 |
| PublicationDateYYYYMMDD | 2023-07-01 |
| PublicationDate_xml | – month: 07 year: 2023 text: 2023-Jul-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Japan |
| PublicationPlace_xml | – name: Japan |
| PublicationTitle | Journal of Atherosclerosis and Thrombosis |
| PublicationTitleAlternate | JAT |
| PublicationYear | 2023 |
| Publisher | Japan Atherosclerosis Society |
| Publisher_xml | – name: Japan Atherosclerosis Society |
| References | 13) Ueshima H, Kadowaki T, Hisamatsu T, Fujiyoshi A, Miura K, Ohkubo T, Sekikawa A, Kadota A, Kadowaki S, Nakamura Y, Miyagawa N, Okamura T, Kita Y, Takashima N, Kashiwagi A, Maegawa H, Horie M, Yamamoto T, Kimura T and Kita T. Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population. Atherosclerosis, 2016; 246: 141-147 32) Nagasawa SY, Okamura T, Iso H, Tamakoshi A, Yamada M, Watanabe M, Murakami Y, Miura K and Ueshima H. Relation between serum total cholesterol level and cardiovascular disease stratified by sex and age group: a pooled analysis of 65 594 individuals from 10 cohort studies in Japan. J Am Heart Assoc, 2012; 1: e001974 18) Essalmani R, Susan-Resiga D, Chamberland A, Abifadel M, Creemers JW, Boileau C, Seidah NG and Prat A. In vivo evidence that furin from hepatocytes inactivates PCSK9. J Biol Chem, 2011; 286: 4257-4263 4) Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM and Nissen SE. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. Jama, 2016; 316: 2373-2384 28) Lakoski SG, Lagace TA, Cohen JC, Horton JD and Hobbs HH. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab, 2009; 94: 2537-2543 31) Hirata A, Kakino A, Okamura T, Usami Y, Fujita Y, Kadota A, Fujiyoshi A, Hisamatsu T, Kondo K, Segawa H, Sawamura T, Miura K and Ueshima H. The relationship between serum levels of LOX-1 ligand containing ApoAI as a novel marker of dysfunctional HDL and coronary artery calcification in middle-aged Japanese men. Atherosclerosis, 2020; 313: 20-25 37) Xie W, Liu J, Wang W, Wang M, Qi Y, Zhao F, Sun J, Liu J, Li Y and Zhao D. Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study. Int J Cardiol, 2016; 215: 293-298 17) Benjannet S, Rhainds D, Hamelin J, Nassoury N and Seidah NG. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem, 2006; 281: 30561-30572 25) Budoff MJ, Shaw LJ, Liu ST, Weinstein SR, Mosler TP, Tseng PH, Flores FR, Callister TQ, Raggi P and Berman DS. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol, 2007; 49: 1860-1870 26) Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol, 2004; 159: 702-706 29) Peng J, Liu MM, Jin JL, Cao YX, Guo YL, Wu NQ, Zhu CG, Dong Q, Sun J, Xu RX and Li JJ. Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study. Cardiovasc Diabetol, 2020; 19: 167 30) Hamamura H, Adachi H, Enomoto M, Fukami A, Nakamura S, Nohara Y, Morikawa N, Sakaue A, Toyomasu K, Yamamoto M and Fukumoto Y. Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population. J Atheroscler Thromb, 2021; 28: 329-337 7) Laugsand LE, Åsvold BO, Vatten LJ, Janszky I, Platou CG, Michelsen AE, Damås JK, Aukrust P and Ueland T. Circulating PCSK9 and Risk of Myocardial Infarction: The HUNT Study in Norway. JACC Basic Transl Sci, 2016; 1: 568-575 22) Sekikawa A, Curb JD, Edmundowicz D, Okamura T, Choo J, Fujiyoshi A, Masaki K, Miura K, Kuller LH, Shin C and Ueshima H. Coronary artery calcification by computed tomography in epidemiologic research and cardiovascular disease prevention. J Epidemiol, 2012; 22: 188-198 33) Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C and Williams B. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol, 2022; 29: 5-115 38) Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A and Seidah NG. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem, 2008; 283: 2363-2372 6) Leander K, Mälarstig A, Van’t Hooft FM, Hyde C, Hellénius ML, Troutt JS, Konrad RJ, Öhrvik J, Hamsten A and de Faire U. Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors. Circulation, 2016; 133: 1230-1239 9) Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C and Williams B. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J, 2021; 42: 3227-3337 16) Friedewald WT, Levy RI and Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18: 499-502 42) Gaudet D, Kereiakes DJ, McKenney JM, Roth EM, Hanotin C, Gipe D, Du Y, Ferrand AC, Ginsberg HN and Stein EA. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol, 2014; 114: 711-715 41) Lamon-Fava S, Marcovina SM, Albers JJ, Kennedy H, DeLuca C, White CC, Cupples LA, McNamara JR, Seman LJ, Bongard V and Schaefer EJ. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res, 2011; 52: 1181-1187 1) Horton JD, Cohen JC and Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res, 2009; 50 Suppl: S172-7 8) Vlachopoulos C, Terentes-Printzios D, Georgiopoulos G, Skoumas I, Koutagiar I, Ioakeimidis N, Stefanadis C and Tousoulis D. Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis. Atherosclerosis, 2016; 252: 50-60 19) Hori M, Ishihara M, Yuasa Y, Makino H, Yanagi K, Tamanaha T, Kishimoto I, Kujiraoka T, Hattori H and Harada-Shiba M. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9. J Clin Endocrinol Metab, 2015; 100: E41-9 39) Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, Kim JB, Scott R, Wasserman SM and Bays H. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol, 2014; 63: 2531-2540 5) Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD and Zeiher AM. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med, 2018; 379: 2097-2107 24) Sekikawa A, Curb JD, Ueshima H, El-Saed A, Kadowaki T, Abbott RD, Evans RW, Rodriguez BL, Okamura T, Sutton-Tyrrell K, Nakamura Y, Masaki K, Edmundowicz D, Kashiwagi A, Willcox BJ, Takamiya T, Mitsunami K, Seto TB, Murata K, White RL and Kuller LH. Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J Am Coll Cardiol, 2008; 52: 417-424 15) Nozue T. Lipid Lowering Therapy and Circulating PCSK9 Concentration. J Atheroscler Thromb, 2017; 24: 895-907 23) Sekikawa A, Ueshima H, Kadowaki T, El-Saed A, Okamura T, Takamiya T, Kashiwagi A, Edmundowicz D, Murata K, Sutton-Tyrrell K, Maegawa H, Evans RW, Kita Y and Kuller LH. Less subclinical atherosclerosis in Japanese men in Japan than in White men in the United States in the post-World War II birth cohort. Am J Epidemiol, 2007; 165: 617-624 44) Furuhashi M, Kataoka Y, Nishikawa R, Koyama M, Sakai A, Higashiura Y, Tanaka M, Saitoh S, Shimamoto K and Ohnishi H. Circulating PCSK7 Level is Independently Associated with Obesity, Triglycerides Level and Fatty Liver Index in a General Population without Medication. J Atheroscler Thromb, 2022; 29: 1275-1284 12) Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Jr., Sperling L, Virani SS and Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019; 139: e1046-e1081 35) Slimani A, Harira Y, Trabelsi I, Jomaa W, Maatouk F, Hamda KB and Slimane MN. Effect of E670G Polymorphism in PCSK9 Gene on the Risk and Severity of Coronary Heart Disease and Ischemic Stroke in a Tunisian Cohort. J Mol Neurosci, 2014; 53: 150-157 10) Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population. Circ J, 2006; 70: 1249-1255 21) Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamo 22 44 23 24 25 26 27 28 29 30 31 10 32 11 33 12 34 13 35 14 36 15 37 16 38 17 39 18 19 1 2 3 4 5 6 7 8 9 40 41 20 42 21 43 |
| References_xml | – reference: 7) Laugsand LE, Åsvold BO, Vatten LJ, Janszky I, Platou CG, Michelsen AE, Damås JK, Aukrust P and Ueland T. Circulating PCSK9 and Risk of Myocardial Infarction: The HUNT Study in Norway. JACC Basic Transl Sci, 2016; 1: 568-575 – reference: 20) Kataoka Y, Harada-Shiba M, Nakao K, Nakashima T, Kawakami S, Fujino M, Kanaya T, Nagai T, Tahara Y, Asaumi Y, Hori M, Ogura M, Goto Y, Noguchi T and Yasuda S. Mature proprotein convertase subtilisin/kexin type 9, coronary atheroma burden, and vessel remodeling in heterozygous familial hypercholesterolemia. J Clin Lipidol, 2017; 11: 413-421.e3 – reference: 38) Poirier S, Mayer G, Benjannet S, Bergeron E, Marcinkiewicz J, Nassoury N, Mayer H, Nimpf J, Prat A and Seidah NG. The proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2. J Biol Chem, 2008; 283: 2363-2372 – reference: 12) Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC, Jr., Sperling L, Virani SS and Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019; 139: e1046-e1081 – reference: 19) Hori M, Ishihara M, Yuasa Y, Makino H, Yanagi K, Tamanaha T, Kishimoto I, Kujiraoka T, Hattori H and Harada-Shiba M. Removal of plasma mature and furin-cleaved proprotein convertase subtilisin/kexin 9 by low-density lipoprotein-apheresis in familial hypercholesterolemia: development and application of a new assay for PCSK9. J Clin Endocrinol Metab, 2015; 100: E41-9 – reference: 32) Nagasawa SY, Okamura T, Iso H, Tamakoshi A, Yamada M, Watanabe M, Murakami Y, Miura K and Ueshima H. Relation between serum total cholesterol level and cardiovascular disease stratified by sex and age group: a pooled analysis of 65 594 individuals from 10 cohort studies in Japan. J Am Heart Assoc, 2012; 1: e001974 – reference: 41) Lamon-Fava S, Marcovina SM, Albers JJ, Kennedy H, DeLuca C, White CC, Cupples LA, McNamara JR, Seman LJ, Bongard V and Schaefer EJ. Lipoprotein(a) levels, apo(a) isoform size, and coronary heart disease risk in the Framingham Offspring Study. J Lipid Res, 2011; 52: 1181-1187 – reference: 13) Ueshima H, Kadowaki T, Hisamatsu T, Fujiyoshi A, Miura K, Ohkubo T, Sekikawa A, Kadota A, Kadowaki S, Nakamura Y, Miyagawa N, Okamura T, Kita Y, Takashima N, Kashiwagi A, Maegawa H, Horie M, Yamamoto T, Kimura T and Kita T. Lipoprotein-associated phospholipase A2 is related to risk of subclinical atherosclerosis but is not supported by Mendelian randomization analysis in a general Japanese population. Atherosclerosis, 2016; 246: 141-147 – reference: 44) Furuhashi M, Kataoka Y, Nishikawa R, Koyama M, Sakai A, Higashiura Y, Tanaka M, Saitoh S, Shimamoto K and Ohnishi H. Circulating PCSK7 Level is Independently Associated with Obesity, Triglycerides Level and Fatty Liver Index in a General Population without Medication. J Atheroscler Thromb, 2022; 29: 1275-1284 – reference: 15) Nozue T. Lipid Lowering Therapy and Circulating PCSK9 Concentration. J Atheroscler Thromb, 2017; 24: 895-907 – reference: 14) Kadota A, Miura K, Okamura T, Fujiyoshi A, Ohkubo T, Kadowaki T, Takashima N, Hisamatsu T, Nakamura Y, Kasagi F, Maegawa H, Kashiwagi A and Ueshima H. Carotid intima-media thickness and plaque in apparently healthy Japanese individuals with an estimated 10-year absolute risk of CAD death according to the Japan Atherosclerosis Society (JAS) guidelines 2012: the Shiga Epidemiological Study of Subclinical Atherosclerosis (SESSA). J Atheroscler Thromb, 2013; 20: 755-766 – reference: 21) Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Jr. and Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol, 1990; 15: 827-832 – reference: 29) Peng J, Liu MM, Jin JL, Cao YX, Guo YL, Wu NQ, Zhu CG, Dong Q, Sun J, Xu RX and Li JJ. Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study. Cardiovasc Diabetol, 2020; 19: 167 – reference: 42) Gaudet D, Kereiakes DJ, McKenney JM, Roth EM, Hanotin C, Gipe D, Du Y, Ferrand AC, Ginsberg HN and Stein EA. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol, 2014; 114: 711-715 – reference: 8) Vlachopoulos C, Terentes-Printzios D, Georgiopoulos G, Skoumas I, Koutagiar I, Ioakeimidis N, Stefanadis C and Tousoulis D. Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis. Atherosclerosis, 2016; 252: 50-60 – reference: 11) Gepner AD, Young R, Delaney JA, Tattersall MC, Blaha MJ, Post WS, Gottesman RF, Kronmal R, Budoff MJ, Burke GL, Folsom AR, Liu K, Kaufman J and Stein JH. Comparison of coronary artery calcium presence, carotid plaque presence, and carotid intima-media thickness for cardiovascular disease prediction in the Multi-Ethnic Study of Atherosclerosis. Circ Cardiovasc Imaging, 2015; 8 – reference: 26) Zou G. A modified poisson regression approach to prospective studies with binary data. Am J Epidemiol, 2004; 159: 702-706 – reference: 30) Hamamura H, Adachi H, Enomoto M, Fukami A, Nakamura S, Nohara Y, Morikawa N, Sakaue A, Toyomasu K, Yamamoto M and Fukumoto Y. Serum Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) is Independently Associated with Insulin Resistance, Triglycerides, Lipoprotein(a) Levels but not Low-Density Lipoprotein Cholesterol Levels in a General Population. J Atheroscler Thromb, 2021; 28: 329-337 – reference: 22) Sekikawa A, Curb JD, Edmundowicz D, Okamura T, Choo J, Fujiyoshi A, Masaki K, Miura K, Kuller LH, Shin C and Ueshima H. Coronary artery calcification by computed tomography in epidemiologic research and cardiovascular disease prevention. J Epidemiol, 2012; 22: 188-198 – reference: 27) Alonso R, Mata P, Muñiz O, Fuentes-Jimenez F, Díaz JL, Zambón D, Tomás M, Martin C, Moyon T, Croyal M, Thedrez A and Lambert G. PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia. Atherosclerosis, 2016; 254: 249-253 – reference: 23) Sekikawa A, Ueshima H, Kadowaki T, El-Saed A, Okamura T, Takamiya T, Kashiwagi A, Edmundowicz D, Murata K, Sutton-Tyrrell K, Maegawa H, Evans RW, Kita Y and Kuller LH. Less subclinical atherosclerosis in Japanese men in Japan than in White men in the United States in the post-World War II birth cohort. Am J Epidemiol, 2007; 165: 617-624 – reference: 39) Koren MJ, Lundqvist P, Bolognese M, Neutel JM, Monsalvo ML, Yang J, Kim JB, Scott R, Wasserman SM and Bays H. Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab. J Am Coll Cardiol, 2014; 63: 2531-2540 – reference: 6) Leander K, Mälarstig A, Van’t Hooft FM, Hyde C, Hellénius ML, Troutt JS, Konrad RJ, Öhrvik J, Hamsten A and de Faire U. Circulating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Predicts Future Risk of Cardiovascular Events Independently of Established Risk Factors. Circulation, 2016; 133: 1230-1239 – reference: 24) Sekikawa A, Curb JD, Ueshima H, El-Saed A, Kadowaki T, Abbott RD, Evans RW, Rodriguez BL, Okamura T, Sutton-Tyrrell K, Nakamura Y, Masaki K, Edmundowicz D, Kashiwagi A, Willcox BJ, Takamiya T, Mitsunami K, Seto TB, Murata K, White RL and Kuller LH. Marine-derived n-3 fatty acids and atherosclerosis in Japanese, Japanese-American, and white men: a cross-sectional study. J Am Coll Cardiol, 2008; 52: 417-424 – reference: 35) Slimani A, Harira Y, Trabelsi I, Jomaa W, Maatouk F, Hamda KB and Slimane MN. Effect of E670G Polymorphism in PCSK9 Gene on the Risk and Severity of Coronary Heart Disease and Ischemic Stroke in a Tunisian Cohort. J Mol Neurosci, 2014; 53: 150-157 – reference: 3) Seidah NG, Awan Z, Chrétien M and Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res, 2014; 114: 1022-1036 – reference: 5) Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD and Zeiher AM. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med, 2018; 379: 2097-2107 – reference: 16) Friedewald WT, Levy RI and Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 1972; 18: 499-502 – reference: 18) Essalmani R, Susan-Resiga D, Chamberland A, Abifadel M, Creemers JW, Boileau C, Seidah NG and Prat A. In vivo evidence that furin from hepatocytes inactivates PCSK9. J Biol Chem, 2011; 286: 4257-4263 – reference: 37) Xie W, Liu J, Wang W, Wang M, Qi Y, Zhao F, Sun J, Liu J, Li Y and Zhao D. Association between plasma PCSK9 levels and 10-year progression of carotid atherosclerosis beyond LDL-C: A cohort study. Int J Cardiol, 2016; 215: 293-298 – reference: 4) Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM and Nissen SE. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. Jama, 2016; 316: 2373-2384 – reference: 31) Hirata A, Kakino A, Okamura T, Usami Y, Fujita Y, Kadota A, Fujiyoshi A, Hisamatsu T, Kondo K, Segawa H, Sawamura T, Miura K and Ueshima H. The relationship between serum levels of LOX-1 ligand containing ApoAI as a novel marker of dysfunctional HDL and coronary artery calcification in middle-aged Japanese men. Atherosclerosis, 2020; 313: 20-25 – reference: 33) Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C and Williams B. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol, 2022; 29: 5-115 – reference: 10) Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population. Circ J, 2006; 70: 1249-1255 – reference: 25) Budoff MJ, Shaw LJ, Liu ST, Weinstein SR, Mosler TP, Tseng PH, Flores FR, Callister TQ, Raggi P and Berman DS. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol, 2007; 49: 1860-1870 – reference: 40) Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM and Stein EA. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. New Engl J Med, 2014; 370: 1809-1819 – reference: 2) Stoekenbroek RM, Lambert G, Cariou B and Hovingh GK. Inhibiting PCSK9 - biology beyond LDL control. Nat Rev Endocrinol, 2018; 15: 52-62 – reference: 1) Horton JD, Cohen JC and Hobbs HH. PCSK9: a convertase that coordinates LDL catabolism. J Lipid Res, 2009; 50 Suppl: S172-7 – reference: 9) Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, Benetos A, Biffi A, Boavida JM, Capodanno D, Cosyns B, Crawford C, Davos CH, Desormais I, Di Angelantonio E, Franco OH, Halvorsen S, Hobbs FDR, Hollander M, Jankowska EA, Michal M, Sacco S, Sattar N, Tokgozoglu L, Tonstad S, Tsioufis KP, van Dis I, van Gelder IC, Wanner C and Williams B. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J, 2021; 42: 3227-3337 – reference: 28) Lakoski SG, Lagace TA, Cohen JC, Horton JD and Hobbs HH. Genetic and metabolic determinants of plasma PCSK9 levels. J Clin Endocrinol Metab, 2009; 94: 2537-2543 – reference: 36) Tóth Š, Fedačko J, Pekárová T, Hertelyová Z, Katz M, Mughees A, Kuzma J, Štefanič P, Kopolovets I and Pella D. Elevated Circulating PCSK9 Concentrations Predict Subclinical Atherosclerotic Changes in Low Risk Obese and Non-Obese Patients. Cardiol Ther, 2017; 6: 281-289 – reference: 43) Kataoka Y, Harada-Shiba M, Hori M, Watanabe M, Kokubo Y, Noguchi T, Yasuda S and Miyamoto Y. Circulating Furin-Cleaved Proprotein Convertase Subtilisin/Kexin Type 9 Concentration Predicts Future Coronary Events in Japanese Subjects. JACC: Asia, 2021; 1: 360-368 – reference: 17) Benjannet S, Rhainds D, Hamelin J, Nassoury N and Seidah NG. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem, 2006; 281: 30561-30572 – reference: 34) Huang CC, Fornage M, Lloyd-Jones DM, Wei GS, Boerwinkle E and Liu K. Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study. Circ Cardiovasc Genet, 2009; 2: 354-361 – ident: 10 doi: 10.1253/circj.70.1249 – ident: 33 doi: 10.1093/eurjpc/zwab154 – ident: 2 doi: 10.1038/s41574-018-0110-5 – ident: 36 doi: 10.1007/s40119-017-0092-8 – ident: 32 doi: 10.1161/JAHA.112.001974 – ident: 40 doi: 10.1056/NEJMoa1316222 – ident: 29 doi: 10.1186/s12933-020-01142-0 – ident: 43 doi: 10.1016/j.jacasi.2021.09.003 – ident: 38 doi: 10.1074/jbc.M708098200 – ident: 44 doi: 10.5551/jat.63159 – ident: 22 doi: 10.2188/jea.JE20110138 – ident: 20 doi: 10.1016/j.jacl.2017.01.005 – ident: 25 doi: 10.1016/j.jacc.2006.10.079 – ident: 34 doi: 10.1161/CIRCGENETICS.108.828467 – ident: 11 doi: 10.1161/CIRCIMAGING.114.002262 – ident: 31 doi: 10.1016/j.atherosclerosis.2020.09.013 – ident: 5 doi: 10.1056/NEJMoa1801174 – ident: 21 doi: 10.1016/0735-1097(90)90282-T – ident: 27 doi: 10.1016/j.atherosclerosis.2016.08.038 – ident: 30 doi: 10.5551/jat.56390 – ident: 3 doi: 10.1161/CIRCRESAHA.114.301621 – ident: 24 doi: 10.1016/j.jacc.2008.03.047 – ident: 42 doi: 10.1016/j.amjcard.2014.05.060 – ident: 8 doi: 10.1016/j.atherosclerosis.2016.07.922 – ident: 18 doi: 10.1074/jbc.M110.192104 – ident: 6 doi: 10.1161/CIRCULATIONAHA.115.018531 – ident: 13 doi: 10.1016/j.atherosclerosis.2015.12.027 – ident: 4 doi: 10.1001/jama.2016.16951 – ident: 39 doi: 10.1016/j.jacc.2014.03.018 – ident: 9 doi: 10.1093/eurheartj/ehab484 – ident: 12 doi: 10.1161/CIR.0000000000000624 – ident: 7 doi: 10.1016/j.jacbts.2016.06.007 – ident: 17 doi: 10.1074/jbc.M606495200 – ident: 23 doi: 10.1093/aje/kwk053 – ident: 35 doi: 10.1007/s12031-014-0238-2 – ident: 1 doi: 10.1194/jlr.R800091-JLR200 – ident: 15 doi: 10.5551/jat.RV17012 – ident: 16 doi: 10.1093/clinchem/18.6.499 – ident: 28 doi: 10.1210/jc.2009-0141 – ident: 37 doi: 10.1016/j.ijcard.2016.04.103 – ident: 26 doi: 10.1093/aje/kwh090 – ident: 41 doi: 10.1194/jlr.M012526 – ident: 19 doi: 10.1210/jc.2014-3066 – ident: 14 doi: 10.5551/jat.17244 |
| SSID | ssj0033552 ssib002822083 |
| Score | 2.3698275 |
| Snippet | Aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising new target for reducing low-density lipoprotein cholesterol (LDL-C) and... Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising new target for reducing low-density lipoprotein cholesterol (LDL-C) and cardiovascular... Aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a promising new target for reducing low-density lipoprotein cholesterol (LDL-C) and... |
| SourceID | pubmedcentral proquest pubmed crossref medicalonline jstage |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 767 |
| SubjectTerms | Aged Aged, 80 and over Atherosclerosis Calcium Cholesterol, LDL Coronary artery calcium Coronary Vessels East Asian People Humans Male Middle Aged Original Prevalence Proprotein Convertase 9 Proprotein convertase subtilisin/kexin type 9 Subtilisins |
| Title | Relationship between Serum Proprotein Convertase Subtilisin/Kexin Type 9 Concentration and Prevalence of Coronary Artery Calcium in a Community-Based Sample of Japanese Men |
| URI | https://www.jstage.jst.go.jp/article/jat/30/7/30_63549/_article/-char/en http://mol.medicalonline.jp/library/journal/download?GoodsID=ex7domya/2023/003007/007&name=0767-0777e https://www.ncbi.nlm.nih.gov/pubmed/36123046 https://www.proquest.com/docview/2716087218 https://pubmed.ncbi.nlm.nih.gov/PMC10322734 |
| Volume | 30 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | Journal of Atherosclerosis and Thrombosis, 2023/07/01, Vol.30(7), pp.767-777 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKQNMkhLhTbjKIB6QpW65O8sZATNWm8bRJfYscJ4OwtZlyEQu_iZ_BD-Mc23HSqpOAh1ptfEtzPh8fO-d8JuQd88I0CyJhxX6YWz7jzOI-DHdYGfgid5jIBe5DnnxhszP_aB7MJ5PfI6-ltkn3xM-NcSX_I1W4BnLFKNl_kKxpFC7Ad5AvpCBhSP9KxsaTbexxBaMfndurUlIwqKA-PHQZpitUE01xWdS4G3B4nF9DLi5Ed2MspPw0m94_GcmduAxJki4byHSAHnYH6APaYUyXKKAfaIHv6iiTprM-Qi9gwXLkHMZqRzAX4xmX6D17gx0sTdCyhr8GaVFrl86qXKT4c3jVtCwWbaV2gTt-URqkFPrqMW_qtmsvCrNplH_lP2TWrKjKroSnNOypV0WhNsRNDb314XrGTRZmLqWuQfsgO7A31uf6PY_CbThSzqE6-GN90gjAaJSHFTR7YH0pAtUReK4WEj0e8tTY_hpttzIEdNYtctsNwYLDkPO5cTTywKJzFacV9rRv-tkh233NFaPozndYFyDhw92FelenOFM2LYHWPXlHptHpfXJPy5IeKIA-IJN8-ZBsn2ivjUfk1xinVOOUSpzSAad0wCkdcLovUUoRpTSmKyilgBQ6oJSW57RHKVUopRqlFFrgdA2lVKEUq_UopYDSx-Ts8PPpp5mlTwmxBIuCxvLiIAscHkdpzs6z2M194TlBFrk-Y6Hjuw4LROo6Kedx7rE04K7HA5GB2czslAF2npCtZbnMnxEaerhBwkF18cwXEY9tKG4zGfztZSKekve9mBKhKfTxJJfLBJbSKNwEhJtI4U7JW1P0SvHGbCoUKVmbIlqVyCKenYSYyKImB4MxQfdNyYcVdCRaLdVJfh1m5aLjCY4YpP5FUnL5AfxDAus9WBKEgTMlb3pAJTCn4ItCeNZlWydu6DA7CsH6n5KnCmDmDnvIwr2vQM8UQL761Zxl8U3y1iN3J7JpPb-x0RdkZxjnL8lWU7X5KzD6m_S1HFN_AIfrDXg |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Relationship+between+Serum+Proprotein+Convertase+Subtilisin%2FKexin+Type+9+Concentration+and+Prevalence+of+Coronary+Artery+Calcium+in+a+Community-Based+Sample+of+Japanese+Men&rft.jtitle=Journal+of+atherosclerosis+and+thrombosis&rft.au=Kunimura%2C+Ayako&rft.au=Miura%2C+Katsuyuki&rft.au=Segawa%2C+Hiroyoshi&rft.au=Torii%2C+Sayuki&rft.date=2023-07-01&rft.eissn=1880-3873&rft.volume=30&rft.issue=7&rft.spage=767&rft_id=info:doi/10.5551%2Fjat.63549&rft_id=info%3Apmid%2F36123046&rft.externalDocID=36123046 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1340-3478&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1340-3478&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1340-3478&client=summon |